Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 195940266 approvals110 trials

HK inno.N Corporation

Official website

Spun off from CJ CheilJedang in 2014, HK inno.N is a pharmaceutical company built around its GERD drug K-CAB, alongside ETC and H&B businesses.

As of 2026-10-10, HK inno.N Corporation has 8 Korean MFDS device approvals, 258 Korean MFDS drug approvals, 27 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Spun off from CJ CheilJedang in April 2014 and listed on KOSDAQ in 2021, HK inno.N is a pharmaceutical company acquired by Kolmar Korea in 2018. Its ETC business offers the GERD drug K-CAB (Korea's 30th approved new drug), Lobazet, and Akinzeo, while its H&B business offers Condition, Hutgaesu, and Vionds. It posted 2025 revenue of KRW 1,063.2 billion and operating profit of KRW 110.9 billion, with ETC accounting for 93% of revenue and H&B 7%; K-CAB ranks No. 1 in the peptic ulcer drug market and has expanded into China, the US, India, and South America.

Products & technology

  • K-CABGERD (gastroesophageal reflux disease) treatment
  • Lobazet
  • Akinzeo
  • ConditionHangover relief beverage (H&B business)
  • HutgaesuBeverage (H&B business)
  • ViondsCosmetics brand (H&B business)

Regulatory approvals

data.go.kr

258 Korean MFDS drug approvals · 1963–2026 / 8 Korean MFDS device approvals · 1999–2013

  • MFDS drugPeraMix Inj2026-08-24
    Drug · Prescription · Approval202602443
  • MFDS drugLixien. 15mg tab2026-04-13
    Drug · Prescription · Approval202601037
  • MFDS drugLixien. 30mg tab2026-04-13
    Drug · Prescription · Approval202601038
  • MFDS drugLixien. 60mg tab2026-04-13
    Drug · Prescription · Approval202601039
  • MFDS drugDenbrayce Injection2026-02-04
    Drug · Prescription · Approval202600307
  • MFDS drugIzambia Pre-filled syringe2026-02-04
    Drug · Prescription · Approval202600308
  • MFDS drugPlasma Solution D Inj.2025-12-15
    Drug · Prescription · Approval202503272
  • MFDS drugZepitor Tab. 10/5mg2025-11-27
    Drug · Prescription · Approval202503099
  • MFDS drugExone Plus Tab. 10/160/12.5mg2025-11-18
    Drug · Prescription · Approval202502989
  • MFDS drugExone Plus Tab. 10/160/25mg2025-11-18
    Drug · Prescription · Approval202502990
  • MFDS drugExone Plus Tab. 5/160/12.5mg2025-11-18
    Drug · Prescription · Approval202502991
  • MFDS drugExone Plus Tab. 5/80/12.5mg2025-11-18
    Drug · Prescription · Approval202502992
Show 68 more
  • MFDS drugGinkgo.N Tab. 240mg2024-11-15
    Drug · OTC · Notification202402698
  • MFDS drugDapa.N Jenta Tab. 10/5mg2024-04-22
    Drug · Prescription · Approval202400937
  • MFDS drugLina N Duo XR Tab. 5/1000mgRevoked2024-03-18
    Drug · Prescription · Approval202400568
  • MFDS drugLina N Duo XR Tab. 2.5/1000mgRevoked2024-03-18
    Drug · Prescription · Approval202400570
  • MFDS drugExone-R Tablet 5/80/2.5mg2023-09-25
    Drug · Prescription · Approval202302824
  • MFDS drugExone-R Tablet 5/160/2.5mg2023-09-25
    Drug · Prescription · Approval202302825
  • MFDS drugOmapplusone Inj.2023-09-07
    Drug · Prescription · Approval202302670
  • MFDS drugOmapplusone Peri Inj.2023-09-07
    Drug · Prescription · Approval202302671
  • MFDS drugDapa N Met XR Tab. 10/500mg2023-06-21
    Drug · Prescription · Approval202301905
  • MFDS drugDapa.N Sita Tab. 10/100mg2023-06-20
    Drug · Prescription · Approval202301872
  • MFDS drugK-CAB ODT 25mg2023-02-28
    Drug · Prescription · Approval202300722
  • MFDS drugRovazet tab. 10/2.5mg2023-02-10
    Drug · Prescription · Approval202300508
  • MFDS drugDapa.N Tab. 10mg2023-01-30
    Drug · Prescription · Approval202300388
  • MFDS drugDapa N Met XR Tab. 10/1000mg2023-01-06
    Drug · Prescription · Approval202300145
  • MFDS drugDapa N Duo XR Tab. 10/500mg2022-11-08
    Drug · Prescription · Approval202204037
  • MFDS drugDapa N Duo XR Tab. 5/500mg2022-11-08
    Drug · Prescription · Approval202204038
  • MFDS drugAkynzeo injectionRevoked2022-10-31
    Drug · Prescription · Approval202203950
  • MFDS drugK-CAB Tab. 25mg2022-07-20
    Drug · Prescription · Approval202203018
  • MFDS drugK-CAB ODT 50mg2022-02-09
    Drug · Prescription · Approval202200635
  • MFDS drugSugamadeon. Inj.2022-02-07
    Drug · Prescription · Approval202200582
  • MFDS drugDapa N Duo XR Tab. 10/1000mg2021-10-08
    Drug · Prescription · Approval202106824
  • MFDS drugDapa N Duo XR Tab. 5/1000mg2021-10-08
    Drug · Prescription · Approval202106825
  • MFDS drugKremezin IDT2021-08-27
    Drug · Prescription · Approval202106217
  • MFDS druginno.N Empagliflozin Tab. 25mgRevoked2021-08-04
    Drug · Prescription · Approval202105730
  • MFDS druginno.N Empagliflozin Tab. 10mgRevoked2021-08-04
    Drug · Prescription · Approval202105731
  • MFDS druginno.N Linagliptin 5mg Tab.Revoked2021-02-23
    Drug · Prescription · Approval202101799
  • MFDS drugZepitor Tab. 10/10mg2021-01-08
    Drug · Prescription · Approval202100240
  • MFDS drugZepitor Tab. 10/40mg2021-01-08
    Drug · Prescription · Approval202100241
  • MFDS drugZepitor Tab. 10/20mg2021-01-08
    Drug · Prescription · Approval202100242
  • MFDS drugExone-A Tab. 5/80/20mg2020-07-24
    Drug · Prescription · Approval202005383
  • MFDS drugExone-A Tab. 5/80/10mg2020-07-24
    Drug · Prescription · Approval202005384
  • MFDS drugExone-A Tab. 5/160/20mg2020-07-24
    Drug · Prescription · Approval202005385
  • MFDS drugExone-A Tab. 5/160/10mg2020-07-24
    Drug · Prescription · Approval202005386
  • MFDS drugTamlostar SR Tab. 0.4mg2020-04-17
    Drug · Prescription · Approval202002721
  • MFDS drugK-Famcier Tab. 250mg2020-02-18
    Drug · Prescription · Approval202001088
  • MFDS drugK-Tasol LotionRevoked2019-11-23
    Drug · Prescription · Notification201908055
  • MFDS drugFlucle Powder 75mg2019-10-28
    Drug · Prescription · Approval201907510
  • MFDS drugFlucle Powder 45mg2019-10-28
    Drug · Prescription · Approval201907511
  • MFDS drugFlucle Powder 30mg2019-10-28
    Drug · Prescription · Approval201907512
  • MFDS drugK-Tasol OintmentRevoked2019-10-17
    Drug · Prescription · Notification201907327
  • MFDS drugK-Rolfine Nail LacquerRevoked2019-09-09
    Drug · OTC · Notification201906373
  • MFDS drugK-Zerotasone CreamRevoked2019-08-06
    Drug · Prescription · Notification201905524
  • MFDS drugK-Tasol SolutionRevoked2019-07-24
    Drug · Prescription · Notification201905279
  • MFDS drugCilo K CR Cap. 200mg2019-05-31
    Drug · Prescription · Approval201903667
  • MFDS drugCilo K CR Cap. 100mg2019-05-31
    Drug · Prescription · Approval201903668
  • MFDS drugExone-R Tab. 5/80/5mg2019-04-15
    Drug · Prescription · Approval201902300
  • MFDS drugExone-R Tab. 5/80/10mg2019-04-15
    Drug · Prescription · Approval201902301
  • MFDS drugExone-R Tab. 5/160/10mg2019-04-15
    Drug · Prescription · Approval201902302
  • MFDS drugExone-R Tab. 5/160/5mg2019-04-15
    Drug · Prescription · Approval201902303
  • MFDS drugAcetphen Premix Inj.2018-11-07
    Drug · Prescription · Notification201804429
  • MFDS drugFlucle Cap. 75mg2018-10-31
    Drug · Prescription · Approval201804340
  • MFDS drugErdokle Cap.2018-09-07
    Drug · OTC · Notification201803649
  • MFDS drugAtomet XR Tab. 10/1000mg2018-08-16
    Drug · Prescription · Approval201803343
  • MFDS drugK-CAB Tab. 50mg2018-07-05
    Drug · Prescription · Approval201802815
  • MFDS drugAkynzeo Cap.2018-06-28
    Drug · Prescription · Approval201802685
  • MFDS drugAtomet XR Tab. 20/500mg2018-05-10
    Drug · Prescription · Approval201801995
  • MFDS drugAtomet XR Tab. 20/750mg2018-05-10
    Drug · Prescription · Approval201801996
  • MFDS drugAtomet XR Tab. 10/750mg2018-05-10
    Drug · Prescription · Approval201801997
  • MFDS drugAtomet XR Tab. 10/500mg2018-05-10
    Drug · Prescription · Approval201801998
  • MFDS drugAmocombi Duo Tab. 500mg2017-09-28
    Drug · Prescription · Approval201707301
  • MFDS drugKabalin Caps. 300mg2017-07-31
    Drug · Prescription · Approval201706372
  • MFDS drugFinasteride Tab. 1mg inno.N2017-07-20
    Drug · Prescription · Approval201705805
  • MFDS drugAmocombi Duo Syr.2017-07-07
    Drug · Prescription · Notification201705469
  • MFDS druginno.N Finasteride Tab. 5mg2017-06-22
    Drug · Prescription · Approval201704723
  • MFDS druginno.N Clopidgrel Tab.2017-06-05
    Drug · Prescription · Approval201703070
  • MFDS drugKabalin Cap. 50mg2017-05-29
    Drug · Prescription · Approval201702673
  • MFDS drugKabalin Cap. 25mg2017-05-29
    Drug · Prescription · Approval201702674
  • MFDS drugVesistar Tab. 5mg2017-03-31
    Drug · Prescription · Approval201701572

Showing the 80 most recent of 266 records.

Clinical trials

data.go.kr

110 MFDS clinical trial authorisations · 2012–2026 (Phase 1 70 · Phase 3 19 · Bioequivalence 13 · Phase 2 6 · Phase 4 1)

  • Phase 4IN-1124202026-08-26

    1 trial site

  • Phase 1IN-1124202026-06-19
  • Phase 2IN-2079072026-06-04

    4 trial sites

  • Phase 1IN-1124202026-04-30
  • BioequivalenceIN-G000072026-03-13

    2 trial sites

  • BioequivalenceIN-M000072025-09-19

    2 trial sites

  • Phase 1IN-M00002정2025-09-10

    2 trial sites

  • Phase 3IN-B00009주2025-08-04

    17 trial sites

  • Phase 3IN-B00009주2025-05-07

    25 trial sites

  • Phase 2IN-1153142025-03-12

    13 trial sites

  • Phase 1IN-1141992024-08-29

    2 trial sites

  • BioequivalenceIN-G000022024-04-19

    2 trial sites

Show 68 more
  • Phase 1IN-1124202023-11-09
  • Phase 1IN-1124202023-09-18
  • Phase 1IN-C0042023-02-22

    2 trial sites

  • Phase 1IN-1124202022-11-17
  • Phase 1IN-1153142022-11-15

    5 trial sites

  • Phase 2IN-1124202022-11-14

    3 trial sites

  • BioequivalenceIN-C0332022-07-06

    2 trial sites

  • Phase 1IN-1124202022-04-11
  • Phase 1IN-C0292022-01-27

    2 trial sites

  • BioequivalenceIN-C0342021-12-20

    2 trial sites

  • BioequivalenceIN-C0332021-12-17

    2 trial sites

  • Phase 3IN-C0062021-12-08

    7 trial sites

  • Phase 3IN-C0062021-10-26

    7 trial sites

  • Phase 1IN-1153142021-08-10

    1 trial site

  • Phase 1IN-B009주2021-07-22

    4 trial sites

  • Phase 1IN-C0052021-07-05

    3 trial sites

  • Bioequivalence텔미원정80밀리그램2021-07-02

    2 trial sites

  • Bioequivalence텔미원플러스정80/12.5밀리그램2021-06-29

    2 trial sites

  • Phase 1IN-1153142021-06-22

    1 trial site

  • Phase 1IN-1153142021-06-09

    1 trial site

  • BioequivalenceIN-C0102021-05-12

    1 trial site

  • Bioequivalence로바젯정10/20밀리그램2021-05-03

    1 trial site

  • Bioequivalence로바젯정10/20밀리그램2020-10-30

    1 trial site

  • Bioequivalence이노엔로자탄정100밀리그램2020-10-29

    2 trial sites

  • Phase 1IN-C0042020-10-23

    1 trial site

  • Phase 1IN-C0042020-10-22

    1 trial site

  • Phase 3IN-1124202020-10-07

    4 trial sites

  • Phase 1IN-1124202020-07-31
  • Phase 1IN-A0122020-06-10

    2 trial sites

  • Phase 1IN-B0012020-06-08

    1 trial site

  • Phase 1IN-C0052020-05-25

    1 trial site

  • Phase 1IN-1124202020-05-11

    2 trial sites

  • Phase 1IN-1124202020-04-02
  • Phase 1IN-1153142019-11-25

    1 trial site

  • Bioequivalence로바젯정10/20밀리그램2019-11-04

    1 trial site

  • Phase 1IN-1124202019-10-31
  • Phase 1IN-1124202019-10-25

    1 trial site

  • Phase 1IN-C0092019-10-14

    1 trial site

  • Phase 3aIN-1124202019-08-29
  • Phase 1CJ-400102019-06-10

    1 trial site

  • Phase 1IN-1124202019-04-03
  • Phase 1CJ-300742019-03-28

    1 trial site

  • Phase 1IN-1124202019-01-17
  • Phase 1IN-1141992018-11-14

    1 trial site

  • Phase 1IN-1124202018-11-07
  • Phase 1IN-1124202018-11-06
  • Phase 1CJ-300702018-10-19

    1 trial site

  • Phase 1CJ-300602018-09-14

    1 trial site

  • Phase 1CJ-300752018-09-10

    1 trial site

  • Phase 1CJ-300752018-09-10

    1 trial site

  • Phase 1CJ-300742018-09-07

    1 trial site

  • Phase 1IN-1124202018-04-09
  • Phase 3IN-1124202018-02-07

    4 trial sites

  • Phase 1CJ-300602018-02-01

    1 trial site

  • Phase 1CJ-300562017-11-29

    1 trial site

  • Phase 1IN-1124202017-09-18
  • Phase 3CJ-300612017-06-21

    18 trial sites

  • Phase 3CJ-400012017-02-27

    1 trial site

  • Phase 3CJ-400012017-02-27

    1 trial site

  • Phase 3IN-1124202016-11-30

    5 trial sites

  • Phase 3IN-1124202016-09-26

    9 trial sites

  • Phase 1CJ-300612016-07-27

    1 trial site

  • Phase 1IN-1124202016-04-29
  • Phase 3IN-1124202016-02-18

    4 trial sites

  • Phase 3IN-1124202015-12-15

    11 trial sites

  • Phase 3CJ-300602015-12-03

    20 trial sites

  • Phase 1씨제이테노포비르정(가칭)2015-11-05

    1 trial site

  • Phase 1CJ-300612015-07-30

    1 trial site

Showing the 80 most recent of 110 records.

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 89 more trials

R&D and key agreements

Source: DART corporate disclosure

케이캡 적응증 확장 · 위식도역류질환 · 임상3상(한국), 허가심사중(미국)

JAK-1 저해제(사람용) · 자가면역질환(아토피) · 임상2상(한국), 임상1상 IND준비(미국)

JAK-1 저해제(반려동물용) · 아토피 · 임상3상(한국)

근감소증 치료제 · 근감소증 · 임상2상 IND신청(한국) · Co-research program

IBAT 저해제 · 변비 · 임상1상 완료(한국)

데노수맙 바이오시밀러 · 골다공증 · 품목허가 승인(한국, 유럽) · In-licensed program (2022)

항암 바이오시밀러 · 항암 · 개발사 임상1상·3상(글로벌) · In-licensed program (2025)

GLP-1RA 주사제 · 비만, 당뇨 · 임상3상(한국) · In-licensed program (2024)

두창예방백신 · 3세대두창 · 임상1상 IND준비(한국)

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 17 more publications

Patents

KIPRIS · applicant-matched
Show 227 more patents

AI reads

MAA server logs · IP-verified
81
Times AI engines pulled HK inno.N Corporation's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

78
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

10
live 0
Last 7 days
58
live 3
Last 30 days
81
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot69
  • PerplexityPerplexityBot5
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for HK inno.N Corporation and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Boditech Med Inc.1 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

SHINHUNG CO.,LTD1 shared

Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

DIO Corporation1 shared

DIO Corporation, established in 1988 and listed on KOSDAQ in 2000, manufactures and sells dental implants.

DongBang Medical Co., Ltd.1 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

Chabiotech Co.,Ltd.1 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

Boryung Corporation1 shared

Founded in 1963 and listed in 1988, Boryung is a pharmaceutical and CDMO firm built around its antihypertensive drug Kanarb.

JPI Healthcare Co., Ltd.1 shared

JPI Healthcare, founded 1980, makes X-ray imaging device components and equipment, listed on KOSDAQ in August 2025.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

DONG-A ST CO.,LTD1 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition